The acquisition strengthens Yusen Logistics’ healthcare footprint across Europe, adding specialized transportation, warehousing, digital, and GDP-compliant capabilities to its regional and global network.
Yusen Logistics (Europe), an overseas subsidiary of Yusen Logistics Group, has officially completed the purchase of the Walden Group’s subsidiaries, including Movianto, Eurotranspharma, Transpharma International, and Walden Digital.
The deal strengthens Yusen Logistics’ position in the European healthcare logistics market, while also reflecting its continued focus on expanding transportation and logistics capabilities to support healthcare customers.
"Today marks an important step forward for Yusen Logistics as we officially welcome our new colleagues from Walden Health into our organization,” said Hiroki Harada, CEO of Yusen Logistics Global Management Co., Ltd. “This integration strengthens our position in the healthcare logistics sector and reflects our commitment to delivering best-in-class solutions for customers across Europe and beyond.
“By combining Walden Health’s expertise with Yusen Logistics global network, we will be able to deliver a healthcare logistics platform that is 'second to none' —ensuring quality, reliability, and innovation throughout the supply chain. I am confident that this strong start will accelerate our growth and support the ambitious objectives of our new mid-term plan starting April 2026. Together, we will set new benchmarks for excellence in healthcare logistics."
Each subsidiary brings a different quality to the table in terms of capabilities and the services that they offer. This includes:
As noted previously, the acquisition boosts Yusen Logistics’ position in the European healthcare logistics market and expands its ability to provide specialized transportation and logistics services to healthcare customers who need it most.
“Completing this acquisition is a pivotal moment for Yusen Logistics in Europe. By combining our long-standing regional presence with the specialized expertise of these healthcare professionals, we are strengthening our ability to deliver comprehensive, tailored solutions across the entire supply chain,” commented Minoru Futonaka, managing director of Yusen Logistics (Europe) B.V. “This integration not only expands our footprint but also reinforces our commitment to supporting customers with world-class healthcare logistics. I am very grateful to all colleagues in Europe and worldwide whose dedication and hard work made this achievement possible."
Emphasizing the strategic importance of the integration and its impact on end-to-end healthcare logistics capabilities, Bruno Jacques, deputy managing director of Yusen Logistics (Europe) B.V. and CEO of Yusen Logistics Healthcare (Europe), said, "With Yusen Logistics Healthcare network, we are entering an exciting new chapter by creating a dedicated healthcare platform that connects warehousing, transportation, last-mile delivery, and digital solutions—delivering end-to-end excellence. Our shared mission is clear: protecting product quality and ensuring that essential medicines and healthcare products reach patients safely and on time. I am proud of the remarkable progress Walden Health has achieved and look forward to shaping an even stronger future together with Yusen Logistics."
In other supply chain/logistics news, Samsung Biologics, a contract development and manufacturing organization (CDMO) based in South Korea, revealed that its wholly owned US subsidiary, Samsung Biologics America, is purchasing Human Genome Sciences from GSK for $280 million.2
As a result, the CDMO acquires its first manufacturing site based in the US—based in Rockville, MD—while also representing growth of its global footprint. The deal is expected to close Q1 2026.
References
1. Yusen Logistics Group Completes Acquisition of Walden Health, Strengthening Global Healthcare Logistics Capabilities. Yusen Logistics. December 19, 2025. Accessed December 23, 2025.
2. Saraceno N. Samsung Biologics Enters US Manufacturing Market with $280M GSK Site Acquisition. Pharmaceutical Commerce. December 22, 2025. Accessed December 23, 2025.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
